Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
NCT ID: NCT01302119
Last Updated: 2019-04-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
604 participants
INTERVENTIONAL
2011-02-28
2013-02-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
NCT01270971
Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis
NCT00680134
Study of Different Doses of a Novel Treatment for Onychomycosis
NCT00679965
Study of Different Doses of a Novel Treatment for Onychomycosis
NCT00679770
Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail
NCT01278394
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AN2690 Topical Solution, 5%
AN2690 Topical Solution, 5%
AN2690 Topical Solution, 5%
AN2690 Topical Solution, 5%, applied once daily for 48 weeks
Solution Vehicle
Solution Vehicle
Solution Vehicle
AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AN2690 Topical Solution, 5%
AN2690 Topical Solution, 5%, applied once daily for 48 weeks
Solution Vehicle
AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* KOH positive at screening
* Willingness not to use any other products including nail polish applied to the toenails during the study
* Women of childbearing potential who are currently sexually active must agree to use contraception for the entire study period
Exclusion Criteria
* History of any significant chronic fungal disease other than onychomycosis
* Significant confounding conditions as assessed by study doctor
* Participated in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study
* Pregnancy or lactation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
PfizerCT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigational Site
Phoenix, Arizona, United States
Investigational Site
Novato, California, United States
Investigational Site
Oceanside, California, United States
Investigational Site
San Diego, California, United States
Investigational Site
San Francisco, California, United States
Investigational Site
Santa Rosa, California, United States
Investigational Site
Miami, Florida, United States
Investigational Site
Miami, Florida, United States
Investigational Site
Nampa, Idaho, United States
Investigational Site
Evansville, Indiana, United States
Investigational Site
Ann Arbor, Michigan, United States
Investigational Site
St Louis, Missouri, United States
Investigational Site
Verona, New Jersey, United States
Investigational Site
Albuquerque, New Mexico, United States
Investigational Site
High Point, North Carolina, United States
Investigational Site
Raleigh, North Carolina, United States
Investigational Site
Columbus, Ohio, United States
Investigational Site
Portland, Oregon, United States
Investigational Site
Philadelphia, Pennsylvania, United States
Investigational Site
Greer, South Carolina, United States
Investigational Site
Knoxville, Tennessee, United States
Investigational Site
Dallas, Texas, United States
Investigational Site
San Antonio, Texas, United States
Investigational Site
Salt Lake City, Utah, United States
Investigational Site
Harrisonburg, Virginia, United States
Investigational Site
Norfolk, Virginia, United States
Investigational Site
Barrie, Ontario, Canada
Investigational Site
Markham, Ontario, Canada
Investigational Site
North Bay, Ontario, Canada
Investigational Site
Boucherville, Quebec, Canada
Investigational Site
Montreal, Quebec, Canada
Investigational Site
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AN2690-ONYC-302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.